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OBJECTIVES: To update the 2012 recommendations on pharmacotherapy for
postmenopausal osteoporosis, under the aegis of the Bone Task Force of the French
Society for Rheumatology (SFR) and of the Osteoporosis Research and Information
Group (GRIO), in collaboration with scientific societies (Collège national des
généralistes enseignants, Collège national des gynécologues et obstétriciens français,
Fédération nationale des collèges de gynécologie médicale, Groupe d'étude de la
ménopause et du vieillissement hormonal, Société française de chirurgie
orthopédique, Société française d'endocrinologie, and Société française de gériatrie et
de gérontologie).
METHODS: Updated recommendations were developed by a task force whose
members represented the medical specialties involved in the management of
postmenopausal osteoporosis. The update was based on a literature review and
developed using the method advocated by the French National Authority for Health
(HAS).
DISCUSSION AND CONCLUSION: The updated recommendations place strong
emphasis on the treatment of women with severe fractures, in whom the use of
osteoporosis medications is recommended. All the available osteoporosis medications
are suitable in patients with severe fractures; zoledronic acid deserves preference as
the fist-line drug after a hip fracture. In patients with or without non-severe fractures,
the decision to use osteoporosis medications is based on bone mineral density values
and in challenging cases, on probabilities supplied by prediction tools such as FRAX.
All osteoporosis medications are suitable; raloxifene should be reserved for patients at
low risk for peripheral fractures. The fracture risk should be reevaluated every 2 to 3
years to decide on the best follow-up treatment. These updated recommendations
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